Lilly Makes All Zepbound Doses Available via Direct Pay Program

As of June 2025, Eli Lilly is making all Zepbound (tirzepatide) dose strengths, including the highest doses (12.5 mg and 15 mg), available through its LillyDirect digital health platform and self-pay program.

Starting July 7, 2025, the 12.5 mg and 15 mg single-dose vials will be available at a flat price of $499 per month, with shipments beginning in early August235.

The 2.5 mg dose is priced at $349 per month, while the 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses are all $499 per month through LillyDirect’s Self-Pay Pharmacy Solutions5.

This move expands upon previous availability of the 7.5 mg and 10 mg vials and provides patients and providers broader access to treatment for obesity without insurance coverage requirements5.

The Zepbound Self-Pay Journey Program was initially launched in February 2025 to support patients’ direct access to various vial sizes at reduced, transparent pricing45.

Sources:

2. https://www.pharmexec.com/view/lilly-launches-full-zepbound-dose-access-obesity-lillydirect-self-pay-program

3. https://firstwordpharma.com/story/5973052

4. https://investor.lilly.com/news-releases/news-release-details/lilly-launches-additional-zepbound-vial-doses-and-offers-new

5. https://www.drugtopics.com/view/eli-lilly-adds-highest-doses-of-zepbound-to-online-pharmacy-platform